10 reports

The prominent features of this report are - ##.

  • Clinical Trial
  • Pharmaceutical
  • Targeted Therapy
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

Hoffmann-La Roche Ltd GlaxoSmithKline Plc ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Galapagos NV ## ## ## ## ## ## UCB SA ## ## ## ## ## ## Pamplona Capital Management LLP ## ## ## ## ## ## Kadmon Holdings Inc ## ##

  • Clinical Trial
  • Monoclonal Antibody
  • Targeted Therapy
  • World
  • Novartis AG

Omeros discovered the link between PDE## and (##) addiction and compulsive disorders and (##) movement disorders, and the company holds broad patents in the U. S. and internationally directed to PDE## inhibitors for the treatment of all of these disorders.

  • Personality Disorder
  • Targeted Therapy
  • Therapy
  • United States
  • Product Initiative

The company conducts research in the therapeutic areas of chronic and neuropathic pain, substance abuse and addiction, metabolic disorders, and infectious diseases.

  • Cancer
  • Targeted Therapy
  • United States
  • Product Initiative
  • AstraZeneca PLC

In 2015, we touched the lives of more than ## ## ## patients, ##% more than in 2014, living with severe neurological or immunological disorders.

  • Pharmaceutical
  • Targeted Therapy
  • United States
  • Company Operations
  • UCB S.A.

It focuses its research activities across several therapeutic areas including chronic and neuropathic pain; substance abuse and addiction; metabolic disorders; and infectious diseases.

  • Oncology
  • Targeted Therapy
  • United States
  • Company
  • AstraZeneca PLC

The Company also intends to pursue other addiction disorders including methamphetamine addiction and eating disorders.

  • Cell Therapy
  • Pharmaceutical
  • Research And Development
  • Targeted Therapy
  • Astellas Pharma Inc.

Mechanism of Action Johnson and Johnson is developing JNJ-## for the treatment of alcohol addiction.

  • Infectious Disease
  • Monoclonal Antibody
  • Targeted Therapy
  • Therapy
  • United States

It was also under development for the treatment of chronic insomnia and as an adjunctive therapy for the treatment of bipolar I disorder in adult patients and also for the treatment of acute depressive episodes associated with bipolar I disorder in adult patients

  • Oncology
  • Targeted Therapy
  • United States
  • Company Operations
  • Takeda Pharmaceutical Company Limited

Non-hematologic AEs included: general disorders and administration site conditions (## [##%]), gastrointestinal and metabolism/ nutrition disorders (## [##%] each), infections (## [##%]), respiratory/ thoracic disorders (## [##%]), vascular and skin/ subcutaneo

  • Cancer
  • Leukemia
  • Targeted Therapy
  • Therapy
  • Novartis AG